Conference Proceedings

EARLY-PHENOTYPE LEWIS Y CAR-T CELLS PERSIST BETTER IN VIVO AND INDUCE SOLID TUMOR REGRESSION IN COMBINATION WITH ANTI-PD1

Deborah Meyran, Joe Zhu, Jeanne Butler, Sean Macdonald, Daniela Tantalo, Niko Thio, Kevin Sek, Paul Ekert, Michael Kershaw, Joe Trapani, Phillip Darcy, Paul Neeson

JOURNAL FOR IMMUNOTHERAPY OF CANCER | BMJ PUBLISHING GROUP | Published : 2020

Abstract

BackgroundChimeric antigen receptor (CAR-T) cells are a promising new therapy for patients with cancer. However, in contrast to their success in B cell malignancies, CAR-T cells targeting solid cancers have had limited success so far due to their poor proliferation and poor long-term persistence in vivo. To address this issue, we used naïve T cells to generate second-generation CAR-T cells recognizing the tumor antigen Lewis Y (LeY), termed ‘early’ CAR-T cells.MethodsPurified naïve T cells were activated by CD3/CD28 soluble tetrameric antibody complex, retrovirally transduced (LeY scFv-CD3z-CD28 CAR) and expanded in IL-7/IL-15. The early LeY CAR-T cell function was tested in vitro for cytoto..

View full abstract